Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells

Nature

Volumn 539, Issue 7629, 2016, Pages 443-447

  De Henau, Olivier ^a   Rausch, Matthew ^b   Winkler, David ^b   Campesato, Luis Felipe ^a   Liu, Cailian ^a   Cymerman, Daniel Hirschhorn ^a   Budhu, Sadna ^a   Ghosh, Arnab ^a   Pink, Melissa ^b   Tchaicha, Jeremy ^b   Douglas, Mark ^b   Tibbitts, Thomas ^b   Sharma, Sujata ^b   Proctor, Jennifer ^b   Kosmider, Nicole ^b   White, Kerry ^b   Stern, Howard ^b   Soglia, John ^b   Adams, Julian ^b   Palombella, Vito J ^b   McGovern, Karen ^b   Kutok, Jeffery L ^b   Wolchok, Jedd D ^a,c   Merghoub, Taha ^a   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Infinity Pharmaceuticals Inc   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTINEOPLASTIC AGENT; IMMUNE CHECKPOINT BLOCKING ANTIBODY; IPI 549; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; UNCLASSIFIED DRUG; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE INHIBITOR;

ANTIBODY; APOPTOSIS; CANCER; CELLS AND CELL COMPONENTS; DISEASE CONTROL; DISEASE RESISTANCE; DISEASE TREATMENT; GENE EXPRESSION; IMMUNE SYSTEM; INHIBITOR; PROTEIN; RODENT; TUMOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME INHIBITION; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; C57BL MOUSE; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; ENZYMOLOGY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MALE; MELANOMA; METABOLISM; NEOPLASM METASTASIS; PATHOLOGY; PHENOTYPE;

ANIMALS; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNE TOLERANCE; MALE; MELANOMA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MYELOID CELLS; NEOPLASM METASTASIS; PHENOTYPE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR MICROENVIRONMENT;

EID: 84995948061     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature20554     Document Type: Article

References (25)

1. Khalil, D. N., Smith, E. L., Brentjens, R. J., Wolchok, J. D. The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat. Rev. Clin. Oncol. 13, 273-290 (2016).
2. Coussens, L. M., Zitvogel, L., Palucka, A. K. Neutralizing tumor-promoting chronic inflammation: a magic bullet Science 339, 286-291 (2013).
3. Gajewski, T. F., Schreiber, H., Fu, Y.-X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14, 1014-1022 (2013).
4. Schmid, M. C., Varner, J. A. Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation. J. Oncol. 2010, 201026 (2010).
5. Diaz-Montero, C. M., Finke, J., Montero, A. J. Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications. Semin. Oncol. 41, 174-184 (2014).
6. Gebhardt, C. et al. Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with Ipilimumab. Clin. Cancer Res. 21, 5453-5459 (2015).
7. De Vlaeminck, Y., González-Rascón, A., Goyvaerts, C., Breckpot, K. Cancerassociated myeloid regulatory cells. Front. Immunol. 7, 113 (2016).
8. Highfill, S. L. et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci. Transl. Med. 6, 237ra67 (2014).
9. Meyer, C. et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol. Immunother. 63, 247-257 (2014).
10. Bjoern, J. et al. Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab. OncoImmunology 5, e1100788 (2015).
11. Holmgaard, R. B., Zamarin, D., Lesokhin, A., Merghoub, T., Wolchok, J. D. Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2, 3-dioxygenase-expressing tumors. EBioMedicine 6, 50-58 (2016).
12. Ugel, S., De Sanctis, F., Mandruzzato, S., Bronte, V. Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages. J. Clin. Invest. 125, 3365-3376 (2015).
13. Gabrilovich, D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4, 941-952 (2004).
14. Lesokhin, A. M. et al. Monocytic CCR2+ myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res. 72, 876-886 (2012).
15. Kaneda, M. M. et al. PI3K is a molecular switch that controls immune suppression. Nature http://dx. doi. org/10. 1038/nature19834 (2016).
16. Hirsch, E. et al. Central role for G protein-coupled phosphoinositide 3-kinase in inflammation. Science 287, 1049-1053 (2000).
17. Li, Z. Roles of PLC-2 and-3 and PI3K in chemoattractant-mediated signal transduction. Science 287, 1046-1049 (2000).
18. Schmid, M. C. et al. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3k, a single convergent point promoting tumor inflammation and progression. Cancer Cell 19, 715-727 (2011).
19. Evans, C. A. et al. Discovery of a selective phosphoinositide-3-kinase (PI3K)-inhibitor (IPI-549) as an immuno-oncology clinical candidate. ACS Med. Chem. Lett. 7, 862-867 (2016).
20. Laoui, D. et al. Tumor hypoxia does not drive differentiation of tumorassociated macrophages but rather fine-tunes the M2-like macrophage population. Cancer Res. 74, 24-30 (2014).
21. Movahedi, K. et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 70, 5728-5739 (2010).
22. Larkin, J. et al. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23-34 (2015).
23. Bindea, G. et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39, 782-795 (2013).
24. Overwijk, W. W. et al. Tumour regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 198, 569-580 (2003).
25. Winkler, D. G. et al. PI3K-and PI3K-inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem. Biol. 20, 1364-1374 (2013).